Univ Brest, Inserm, EFS, UMR 1078, GGB, GTCA team, "Gene Transfer and Combined therapeutic Approaches", CHU de Brest, 22 avenue Camille Desmoulins, F-29200, Brest, France.
CHU de Brest, Service de Chirurgie Gynécologique, F-29200, Brest, France.
Cancer Gene Ther. 2023 Jun;30(6):812-821. doi: 10.1038/s41417-023-00590-6. Epub 2023 Jan 30.
Ovarian cancer represents the most lethal gynecological malignancy among women in developed countries. Despite the recent innovations, the improvements in the 5-year survival rate have been insufficient and the management of this disease still remains a challenge. The fact that the majority of patients experience recurrent or resistant disease have substantiated the necessity of an innovative treatment. Among various strategies investigated, the recent strides made in gene delivery techniques have made gene therapy, including suicide gene strategies, a potential alternative for treating ovarian cancer. Various suicide gene candidates, which are capable of promoting cancer cell apoptosis directly after its entry or indirectly by prodrug administration, can be separated into three systems using enzyme-coding, toxin or pro-apoptotic genes. With this review, we aim to provide an overview of different suicide genes depending on therapeutic strategies, the vectors used to deliver these transgenes specifically to malignant cells, and the combined treatments of these genes with various therapeutic regimens.
在发达国家，卵巢癌是女性中最致命的妇科恶性肿瘤。尽管最近有了创新，但 5 年生存率的提高仍然不足，这种疾病的治疗仍然是一个挑战。大多数患者经历复发或耐药性疾病的事实证实了创新治疗的必要性。在各种研究的策略中，最近在基因传递技术方面取得的进展使得基因治疗，包括自杀基因策略，成为治疗卵巢癌的一种潜在选择。各种自杀基因候选物，能够在进入细胞后直接或通过前药给药间接促进癌细胞凋亡，可以使用编码酶、毒素或促凋亡基因的三种系统进行分离。通过这篇综述，我们旨在概述根据治疗策略、用于将这些转基因专门递送到恶性细胞的载体以及这些基因与各种治疗方案联合治疗的不同自杀基因。
